21 U.S. Code § 360bbb–8b - Use of clinical investigation data from outside the United States

Status message

There is 1 Update Pending. Select the tab below to view.
(a) In general
In determining whether to approve, license, or clear a drug or device pursuant to an application submitted under this subchapter, the Secretary shall accept data from clinical investigations conducted outside of the United States, including the European Union, if the applicant demonstrates that such data are adequate under applicable standards to support approval, licensure, or clearance of the drug or device in the United States.
(b) Notice to sponsor
If the Secretary finds under subsection (a) that the data from clinical investigations conducted outside the United States, including in the European Union, are inadequate for the purpose of making a determination on approval, clearance, or licensure of a drug or device pursuant to an application submitted under this subchapter, the Secretary shall provide written notice to the sponsor of the application of such finding and include the rationale for such finding.

Source

(June 25, 1938, ch. 675, § 569B, as added Pub. L. 112–144, title XI, § 1123,July 9, 2012, 126 Stat. 1113.)

The table below lists the classification updates, since Jan. 3, 2012, for this section. Updates to a broader range of sections may be found at the update page for containing chapter, title, etc.

The most recent Classification Table update that we have noticed was Tuesday, August 13, 2013

An empty table indicates that we see no relevant changes listed in the classification tables. If you suspect that our system may be missing something, please double-check with the Office of the Law Revision Counsel.

21 USCDescription of ChangeSession YearPublic LawStatutes at Large
§ 360bbb-8bnew2012112-144 [Sec.] 1123 "569B"126 Stat. 1113

 

LII has no control over and does not endorse any external Internet site that contains links to or references LII.